{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-072016","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.058349+00:00","generated_at":"2026-05-21T04:42:49.741987+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Precision BioSciences Q1 net loss $20.6M; revenue drops to <$0.1M; PBGENE-DMD accelerated","bullets":["Revenue less than $0.1M vs $17.6M in Q1 2024; net loss of $20.6M ($2.21/share) vs net income $8.6M ($1.70/share) a year ago.","Cash, equivalents and restricted cash ~$100M; cash runway expected into H2 2026, funding PBGENE-HBV and PBGENE-DMD through Phase 1 data.","PBGENE-HBV cleared for U.S. Phase 1 (FDA IND) and UK (MHRA); Fast Track designation granted; initial safety data presented at EASL.","PBGENE-DMD prioritized as second wholly owned program; IND/CTA target in 2025 with clinical data expected in 2026.","PBGENE-3243 development paused to focus resources on HBV and DMD programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-072016","json":"https://secwatch.observer/filing/0000950170-25-072016.json","markdown":"https://secwatch.observer/filing/0000950170-25-072016.md","text":"https://secwatch.observer/filing/0000950170-25-072016.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017025072016/0000950170-25-072016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017025072016/dtil-20250515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:42:49.741987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}